 |
Results of a phase II clinical trial on the safety and effectiveness of low dose naltrexone (LDN) as a symptom-relief treatment for people with MS have been published in the journal Annals of Neurology.
To read more, as reported by the UK MS Society, click here.
Source: UK MS Society
|
